CA2967350C - Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof - Google Patents

Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Download PDF

Info

Publication number
CA2967350C
CA2967350C CA2967350A CA2967350A CA2967350C CA 2967350 C CA2967350 C CA 2967350C CA 2967350 A CA2967350 A CA 2967350A CA 2967350 A CA2967350 A CA 2967350A CA 2967350 C CA2967350 C CA 2967350C
Authority
CA
Canada
Prior art keywords
antibody
humanized
cells
bispecific antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967350A
Other languages
English (en)
French (fr)
Other versions
CA2967350A1 (en
Inventor
Soldano Ferrone
Nai-Kong V. Cheung
Ming Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Original Assignee
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Memorial Sloan Kettering Cancer Center filed Critical General Hospital Corp
Publication of CA2967350A1 publication Critical patent/CA2967350A1/en
Application granted granted Critical
Publication of CA2967350C publication Critical patent/CA2967350C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2967350A 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Active CA2967350C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078849P 2014-11-12 2014-11-12
US62/078,849 2014-11-12
PCT/US2015/060465 WO2016077638A1 (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CA2967350A1 CA2967350A1 (en) 2016-05-19
CA2967350C true CA2967350C (en) 2021-11-23

Family

ID=55955081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967350A Active CA2967350C (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Country Status (6)

Country Link
US (1) US11091547B2 (enExample)
EP (1) EP3218413A4 (enExample)
JP (1) JP6779873B2 (enExample)
AU (1) AU2015346205B2 (enExample)
CA (1) CA2967350C (enExample)
WO (1) WO2016077638A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
WO2019240935A1 (en) * 2018-06-13 2019-12-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
MA53982A (fr) 2018-10-23 2022-01-26 Dragonfly Therapeutics Inc Protéines hétérodimères fusionnées à un fragment fc
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP7644777B2 (ja) 2020-04-22 2025-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
CN111575241B (zh) * 2020-05-29 2022-09-13 复旦大学附属眼耳鼻喉科医院 一种嵌合硫酸软骨素蛋白多糖4受体的t淋巴细胞及其制备方法和用途
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US20230242666A1 (en) * 2020-06-29 2023-08-03 Cell Medica, Inc. Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
US20250129160A1 (en) * 2021-06-04 2025-04-24 Amgen Research (Munich) Gmbh T cell engager molecules and uses thereof
JP2024546096A (ja) * 2021-12-07 2024-12-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ コンドロイチン硫酸プロテオグリカン（ｃｓｐｇ４）ポリペプチドの結合剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
WO2008121876A2 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
CA2737758C (en) * 2008-09-19 2017-10-31 Soldano Ferrone Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
EP2334701A4 (en) * 2008-10-16 2014-01-08 Univ Pittsburgh FULLY HUMAN ANTIBODIES AGAINST ANTIGENES ASSOCIATED WITH MELANOMA OF HIGH MOLECULAR WEIGHT AND USES THEREOF
WO2011009090A1 (en) 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
PT2483310E (pt) 2009-09-29 2014-10-07 Roche Glycart Ag Anticorpos bi-específicos agonistas do receptor de morte
JP6029581B2 (ja) * 2010-06-19 2016-11-24 メモリアル スローン−ケタリング キャンサー センター 抗ｇｄ２抗体
WO2012075324A1 (en) * 2010-12-02 2012-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds hmw-maa
WO2013092001A1 (en) * 2011-12-19 2013-06-27 Synimmune Gmbh Bispecific antibody molecule
JP2015504060A (ja) * 2011-12-28 2015-02-05 ノーベルメッド セラピューティクス インコーポレイテッド． アグリコシル化ヒト抗体および融合タンパク質、ならびにその使用
HUE059815T2 (hu) 2012-05-18 2022-12-28 Aptevo Res & Development Llc Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz
PE20151410A1 (es) 2013-02-26 2015-09-18 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
AU2014225788B2 (en) * 2013-03-05 2018-03-29 Baylor College Of Medicine Engager cells for immunotherapy
WO2014165644A2 (en) * 2013-04-04 2014-10-09 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors

Also Published As

Publication number Publication date
AU2015346205A1 (en) 2017-06-01
US11091547B2 (en) 2021-08-17
WO2016077638A1 (en) 2016-05-19
EP3218413A4 (en) 2018-03-28
CA2967350A1 (en) 2016-05-19
JP2017537082A (ja) 2017-12-14
EP3218413A1 (en) 2017-09-20
AU2015346205B2 (en) 2021-07-29
US20170342151A1 (en) 2017-11-30
JP6779873B2 (ja) 2020-11-04

Similar Documents

Publication Publication Date Title
CA2967350C (en) Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US11981742B2 (en) Antibody agents specific for human CD19 and uses thereof
EP3105252B1 (en) Bispecific antibodies for use in stem cell transplantation
KR102089114B1 (ko) 항원 결합 단백질 및 암의 치료를 위한 어드레싱 산물로서 그의 용도
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
RU2773317C2 (ru) Антительные агенты, специфичные к cd19 человека, и их применения
HK40071400A (en) Antibody agents specific for human cd19 and uses thereof
HK40071400B (zh) 对人类cd19具有专一性的抗体药剂和其用途
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof
HK1241907B (zh) 对人类cd19具有专一性的抗体药剂和其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201014